Skip to main content
S&P 5007,617.26+0.87%DOW51,633.11+0.33%NASDAQ26,342.68+1.40%BTC$76,477.00+1.28%ETH$2,456.13+2.89%GOLD$4,408.80+0.49%OIL$100.46-1.92%
Smart Investors Daily
KM

NASDAQ · KMDA

Kamada Ltd.

Healthcare · Drug Manufacturers - Specialty & Generic

$8.19

Up+$0.38 (+4.64%)

Updated Sep 17, 2026, 2:03 PM

SID Score

4.7/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
405.5M
P/E ratio
20.98
Dividend yield
2.44%
52-week range
$6.85 – $9.11
Volume
128.02K
Avg. volume
76.93K

Price performance

KMDA price history

1M range · 20 trading sessions · Daily adjusted prices

KMDA closed at $8.19 after 20 trading sessions, up 3.80% for the selected period.

Last close
$8.19
Period change
+3.80%
Period low
$7.89
Period high
$8.63
Daily close
View OHLC price history
KMDA OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 16, 2026$8.21$8.29$8.10$8.19128.02K
Sep 15, 2026$8.17$8.19$7.995$8.09119.78K
Sep 14, 2026$8.082$8.361$8.05$8.31286.72K
Sep 11, 2026$8.05$8.11$7.90$7.92106.64K
Sep 10, 2026$8.09$8.14$7.97$7.99110.24K
Sep 9, 2026$8.27$8.28$8.16$8.21106.91K
Sep 8, 2026$8.282$8.35$8.20$8.29375.36K
Sep 4, 2026$8.32$8.60$8.32$8.54160.81K
Sep 3, 2026$8.27$8.34$8.215$8.27112.17K
Sep 2, 2026$8.22$8.435$8.19$8.40208.09K
Sep 1, 2026$8.14$8.40$8.13$8.38173K
Aug 31, 2026$8.17$8.29$8.14$8.2394.93K
Aug 28, 2026$8.30$8.35$8.24$8.2955.08K
Aug 27, 2026$8.28$8.38$8.125$8.26107K
Aug 26, 2026$8.51$8.64$8.3101$8.38306.13K
Aug 25, 2026$8.44$8.637$8.44$8.63121.68K
Aug 24, 2026$8.315$8.594$8.315$8.43198.83K
Aug 21, 2026$8.02$8.25$8.02$8.24112.87K
Aug 20, 2026$7.83$8.13$7.80$8.02233.4K
Aug 19, 2026$7.83$7.92$7.78$7.89265.11K

Latest KMDA news

The latest Smart Investors Daily articles mentioning KMDA.

Stock researchCompany · Overview

KMDA research

Overview

Company profile and research snapshot.

Company profile

Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$13.00
Implied upside
—
Analysts
—
KMDA recent ratings
DateFirmRatingTarget
Dec 9, 2025HC Wainwright & Co.Buy—
May 15, 2025BenchmarkBuy—
Mar 21, 2025BenchmarkBuy—
Mar 6, 2025HC Wainwright & Co.Buy—
Jan 10, 2025HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 10, 2026

Kamada to Present at the H.C. Wainwright 28th Annual Global Investment Conference

REHOVOT, Israel, and HOBOKEN, N.J., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that Amir London, Chief Executive Officer, will participate and present at the H.C. Wainwright 28th Annual Global Investment Conference, taking place at the Lotte New York Palace Hotel. Mr. London is sch

Benzinga · Sep 8, 2026

Director At Kamada Exercises Options Worth $77K

In a new SEC filing on September 8, it was revealed that Tsur, Director at Kamada (NASDAQ:KMDA), executed a significant exercise of company stock options. What Happened: Tsur, Director at Kamada, made a strategic move

Yahoo · Sep 3, 2026

Kamada Updates on Withholding Tax Procedures on Previously Announced Cash Dividend to Shareholders

REHOVOT, Israel and HOBOKEN, N.J., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd. (the “Company”) (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, announced today that it has obtained a tax ruling (the “Ruling”) from the Israel Tax Authority (the “ITA”) with respect to the cash dividend of $0.17 (approximately NIS 0.51) per share on the Company’s or

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By